Evidence Explorer · MS-N271 · Supportive physical care · Appraised November 8, 2026
A six-center randomized trial found that adding a specific self-adjusting nighttime sleeve to daytime compression reduced arm excess volume over three months after intensive decongestive therapy. This is device- and maintenance-phase evidence, not proof that every nighttime garment will help.
Evidence at a glance
- Population: 56 women with established upper-limb breast-cancer-related lymphedema after intensive decongestive therapy.
- Intervention: Mobiderm Autofit nighttime sleeve plus usual daytime compression for 90 days.
- Comparator: daytime compression alone.
- Primary result: mean excess arm volume fell 29.2% with nighttime compression and rose 10.7% with daytime compression alone (P=.001).
- Evidence label: positive, device-specific short-term maintenance evidence.
What was studied
Secondary results favored nighttime compression for quality of life, sleep, skin suppleness and thickness. Treatment failure occurred in 3.6% versus 23.1%. The trial was registered as NCT04203069.
The study tested an addition to established daytime care after an intensive phase. It did not test prevention, newly diagnosed swelling, lower-limb disease or unsupervised use of generic sleeves.
What this evidence cannot establish
Fifty-six participants and three months of follow-up limit precision and durability. A branded self-adjusting garment cannot be assumed equivalent to all bandages or sleeves. The trial does not establish fewer cellulitis episodes, reduced cancer recurrence or long-term cost-effectiveness.
Safety and practical context
Night garments should be professionally selected. Remove and seek advice for pain, coldness, discoloration, numbness, pressure marks, skin breakdown or worsening swelling. Cellulitis, suspected thrombosis and uncontrolled heart failure require clinical assessment before compression changes.
Questions for the care team
- Am I in a maintenance phase where added nighttime compression was studied?
- Is this garment or a validated equivalent suitable for my arm shape and skin?
- What objective volume change and symptom response would justify continuing it?
Sources and identifiers
- LYMphoNIGHT randomized trial — PMID 42091704
Funding and conflicts: The accessible PubMed record did not provide enough detail to verify funding or product-sponsor involvement; these remain not verified.
Source access and dates: Original PubMed records and available full texts were checked November 8, 2026. Last literature search November 8, 2026.
Educational evidence summary, not individualized medical advice. Supportive-care outcomes do not demonstrate tumor response, recurrence prevention or longer survival.
